Effect of blood sample type on the measurement of advanced oxidation protein products as a biomarker of inflammation and oxidative stress in hemodialysis patients

• Published in: Biomarkers Vol. 16; no. 2; pp. 129 - 135
• Main Authors: Chen, Yuan-Han, Shi, Wei, Liang, Xin-Ling, Liang, Yong-Zheng, Fu, Xia
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.03.2011; Taylor & Francis
• Subjects: Advanced oxidation protein products; biomarker; Biomarkers - blood; Blood Specimen Collection - methods; Blood Specimen Collection - standards; C-Reactive Protein - analysis; cardiovascular disease; Cardiovascular Diseases - blood; Cross-Sectional Studies; Female; Fibrinogen - adverse effects; Fibrinogen - analysis; Fibrinogen - chemistry; hemodialysis; Humans; Inflammation - blood; Interleukin-6 - blood; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Peroxidase - analysis; Renal Dialysis; sample preparation; Tumor Necrosis Factor-alpha - blood
• ISSN: 1354-750X; 1366-5804; 1366-5804
• DOI: 10.3109/1354750X.2010.535172

Advanced oxidation protein products (AOPP) is widely used as a uremic biomarker, especially for cardiovascular disease. However, it has not been determined whether it is better to measure AOPP in plasma or serum. In this cross-sectional study, which included 102 patients undergoing maintenance hemodialysis, fibrinogen-free serum and defibrinated plasma samples were prepared. AOPP levels from fibrinogen-free samples displayed a stronger correlation with myeloperoxidase activity and levels of C-reactive protein, interleukin-6 and tumor necrosis factor-alpha, as well as prevalent cardiovascular disease, than AOPP levels obtained from plasma samples. These results demonstrated that fibrinogen interferes with the measurement of AOPP.